

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

BA

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07H 21/02, 21/04, C07K 5/00, 14/00,</b> <b>C12N 1/21, C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/00403</b> <b>(43) International Publication Date:</b> 7 January 1999 (07.01.99)
<b>(21) International Application Number:</b> PCT/US98/12820 <b>(22) International Filing Date:</b> 18 June 1998 (18.06.98) <b>(30) Priority Data:</b> 60/051,347 30 June 1997 (30.06.97) US <b>(71) Applicant:</b> THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Suite 350, 900 Welch Road, Palo Alto, CA 94304-1850 (US). <b>(72) Inventors:</b> SCOTT, Matthew, P.; 914 Wing Place, Stanford, CA 94305 (US). SISSON, John, C.; 132 1/2 De La Costa Avenue, Santa Cruz, CA 95060 (US). <b>(74) Agent:</b> SHERWOOD, Pamela, J.; Bozicevic & Reed LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> <i>COSTAL2</i> GENES AND THEIR USES		
<b>(57) Abstract</b>  Methods for isolating <i>costal2</i> genes are provided. The <i>costal2</i> nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity <i>in vivo</i> is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**COSTAL2 GENES AND THEIR USES**

This invention was made with support from the Howard Hughes Medical Institute. The Government may have certain rights in this invention.

5

**INTRODUCTION***Background*

Segment polarity genes were originally discovered as mutations in flies that change the pattern of body segment structures. Among the genes in this class are *hedgehog*, *patched*, and *costal2*. The proteins encoded by these genes form a signaling pathway that regulates key events in early development, and in adult life has been implicated in carcinogenesis. The pathway has been best studied in model organisms such as flies, but it is conserved among all animals. In this pathway, the secreted signaling protein *hedgehog* binds to its receptor, *patched*, on receiving cells. *Costal2* is part of the machinery that then transduces this signal to the nucleus, resulting in changes in gene activation.

*Hedgehog* induces transcription of certain powerful regulatory target genes, while both *patched* and *costal2* act in opposition to keep the target genes turned off. Other components of the pathway required for activation include the seven transmembrane protein, *smoothened*, the kinase *fused*, and *cubitus interruptus*. Experimental data suggests that *hedgehog* binds to *patched* at the cell surface, preventing *patched* from inactivating *smoothened* function. In the presence of *hedgehog* signal, *smoothened* is active, allowing it to send an activating signal to the nucleus. How *hedgehog* and *smoothened* send the activating signal to the nucleus is unknown, but genetic evidence suggests that *fused* and *costal2* are involved. Changes in their activities are thought to allow *cubitus interruptus* to directly activate the transcription of *hedgehog* target genes.

The *hedgehog* signaling pathway has been implicated in several important human disease processes. For example, mutations in *patched* are associated with basal cell carcinomas, developmental abnormalities and brain tumors. The human homolog of *cubitus interruptus*, *GLI*, is an oncogene found in gliomas. One of the human *hedgehog* homologs, *SHH*, has also been implicated in tumorigenesis.

The characterization and identification of *hedgehog* signaling pathway component genes is of great interest, because of their involvement in the control of cellular differentiation and growth regulation.

Relevant Literature

The interaction of *patched* (*PTCH*) and *hedgehog* is described in Chen and Struhl (1996) Cell 87: 553-563. The role of *PTCH* in sporadic basal cell carcinomas is described in Gailani *et al.* (1996) Nature Genet. 14:78-81; Hahn *et al.* (1996) Cell 85: 841-851; and Johnson *et al.* (1996)

Science 272:1668-1671. Evidence that PTCH is a receptor for sonic hedgehog (SHH) is presented in Marigo *et al.* (1996) Nature 384:176-179; and Stone *et al.* (1996) Nature 384:129-134.

Cloning of *SHH* and *IHH* is described in Marigo *et al.* (1995) Genomics 28:44-51. The function of *SHH* is explored in Chiang *et al.* (1996) Nature 383:407-413; and Ericson *et al.* (1996) Cell 87: 661-673.

The regulation of transcription by *cubitus interruptus* is described in Von Ohlen *et al.* (1997) P.N.A.S. 94:2404-2409; Hepker *et al.* (1997) Development 124:549-558; Alexandre *et al.* (1996) Genes Dev. 10:2003-2013; and Dominguez *et al.* (1996) Science 272:1621-1625.

The first description of *costal* was published by Whittle (1974) Heredity 33:139. The interaction of *costal2* with *fused* is described in Preat *et al.* (1993) Genetics 135:1047-1062. Genetic analysis of the region containing the *Drosophila costal2* gene is found in Heitzler *et al.* (1993) Genetics 135:105-115.

Kinesin-like proteins are thought to be motors that bind to microtubules and use ATP to move along them like trains on tracks. Different members of the family are believed to transport different cargos. Kinesins are structurally related to myosin, even though myosin motors (which power muscle) move on actin rather than tubulin tracks, Kull *et al.* (1996) Nature 380:550-555. Kinesins can move toward the positive or the negative terminus of microtubules, and some act to cross-link two or more microtubules. A review of kinesins may be found in Goldstein *et al.* (1993) Annu. Rev. Genet. 27:319-351. The interaction between kinesins and microtubules is explored in Tucker and Goldstein (1997) J Biol Chem 272:9481-9488.

#### SUMMARY OF THE INVENTION

Isolated nucleotide compositions and sequences are provided for *costal2* (*cos2*) genes. The *cos2* nucleic acid compositions find use in identifying homologous or related genes; in producing compositions that modulate the expression or function of its encoded protein, Cos2; for gene therapy; mapping functional regions of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity *in vivo* is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like.

*Cos2* encodes a kinesin-related protein that accumulates preferentially in cells capable of responding to Hh. *Cos2* is cytoplasmic and binds both to microtubules and to the gene products of *fused* (*fu*), and *cubitus interruptus* (*Ci*), suggesting that *Cos2* directly controls the activity of *Ci*. *Cos2* plays a novel role for kinesin-related proteins in regulating signal transduction. The *cos2* protein is useful as an immunogen for producing specific antibodies, in screening for biologically active agents that act in the hedgehog signaling pathway and for therapeutic and prophylactic purposes.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B illustrate genetic maps in the *cos2* region.

Figure 2A shows features in the sequence of *cos2*. Figure 2B is a diagram of the predicted two structure of *cos2*. Figure 2C is an alignment of *cos2* and other kinesin proteins.

5

## DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Nucleic acid compositions encoding *costal-2* (*cos2*) are provided. They are used in identifying homologous or related genes; in producing compositions that modulate the expression or function of its encoded protein; for gene therapy; mapping functional regions of the protein; and in

10

studying associated physiological pathways. The *cos2* gene product is a member of the kinesin superfamily. It directly binds to microtubules in the cytoplasm, and also binds to Ci, suggesting regulation of expression through the sequestration and/or translocation of a transcription factor.

Modulation of *Cos2* gene activity *in vivo* is used for prophylactic and therapeutic purposes, such as treatment of cancer, investigation of *hedgehog* signaling pathway function, identification of

15

cell type based on expression, and the like. The protein is useful as an immunogen for producing specific antibodies, in screening for biologically active agents that act in the hedgehog signaling pathway and for therapeutic and prophylactic purposes.

CHARACTERIZATION OF *COS2*

*Cos2* is widely expressed, typically in cells that also express *patched*. The *Drosophila* gene sequence is provided as SEQ ID NO:1, the encoded polypeptide product as SEQ ID NO:2. The gene product acts to repress expression of *hedgehog* target genes, which include *patched*, members of the transforming growth factor  $\beta$  and *Wnt* gene families. The human gene is predicted to be a tumor suppressor, based on functional similarity to *patched*. *Cos2* is also involved in many

20

25

events in normal development, including formation of the neurons that are depleted in Parkinson's disease, formation of normal limbs and musculature, signaling in gut development, chondrogenesis and proper development of the brain.

Two proteins, the serine/threonine kinase, *fused* (Fu) and the zinc finger protein, *cubitus interruptus* (Ci), are required for transmitting the Hh signal. Ci has homology to the Gli family of

30

transcription factors in vertebrates and is proposed to control directly the transcription of Hh target genes. In extracts of *Drosophila* embryos, Fu and Ci are found associated with the kinesin-related protein, *costal-2* (Cos-2) as part of a high molecular weight complex. Cos-2, like Ptc, functions as a negative regulator of Hh signaling and can bind to microtubules. Cos-2 may inhibit Hh signaling by sequestering Ci in the cytosol to prevent it from activating gene expression. Both Cos-2 and Fu

35

become phosphorylated in response to Hh which suggests that the activities of these proteins are modulated post-transcriptionally.

Many components of the *hedgehog* signaling pathway have been identified and characterized, including the following:

	<b>Drosophila gene</b>	<b>Human hom log</b>	<b>Genbank accession no. human gene</b>
	<i>patched (ptch)</i>	<i>PTCH</i>	U59464
5	<i>hedgehog (hh)</i>	<i>SHH</i>	L38518
		<i>IHH</i>	L38517
		<i>DHH</i>	U59748
	<i>cubitus interruptus (ci)</i>	<i>GLI</i>	X07384
	<i>fused (fu)</i>	<i>serine threonine kinase</i>	-
10	<i>smoothened (smo)</i>	<i>SMO</i>	U84401
	<i>wingless (wg)</i>	<i>WNT gene family</i>	numerous
	<i>Protein Kinase A</i>	<i>PKA</i>	numerous
	<i>decapentaplegic (dpp)</i>	<i>TGF-<math>\beta</math> gene family</i>	numerous

- 15 The availability of isolated genes and gene products in this pathway allows the *in vitro* reconstruction of the pathway and its regulation using human, mouse, or *Drosophila* molecules, or a combination thereof.

#### IDENTIFICATION OF COS2 SEQUENCES

- 20 Homologs of *cos2* are identified by any of a number of methods. A fragment of the *Drosophila* cDNA may be used as a hybridization probe against a cDNA library from the target organism of interest, where low stringency conditions are used. The probe may be a large fragment, or one or more short degenerate primers. The binding of *cos2* to *Ci* and to microtubules can be exploited in various binding assays, e.g. yeast 2-hybrid system, etc., to identify nucleic acids
- 25 encoding *cos2*. A mammalian homolog of *Ci*, i.e. one of the *GLI* family of transcription factors, may be used to identify human and other genes using such a binding assay.

- In an alternative approach, conserved regions between different invertebrate homologs of *cos2* may be used to design primers useful for hybridizing to vertebrate, especially mammalian homologs. Such sequences are selected from regions that are not likely to diverge over
- 30 evolutionary time and are of low degeneracy. The complementary binding sequence will usually be at least 14 nucleotides, preferably at least about 17 nucleotides and usually not more than about 30 nucleotides. Conveniently, amplification reactions are used to generate an initial probe, which can then be used to hybridize to a library; for rapid amplification of cloned ends (RACE); etc. One or more of the resulting clones may then be used to rescreen the library to obtain an extended
- 35 sequence, up to and including the entire coding region, as well as the non-coding 5'- and 3'-sequences. As appropriate, one may sequence all or a portion of the resulting cDNA coding

sequence. The source of mRNA for a cDNA library will use cells where *patched* is known to be expressed, for example embryonic limb bud tissue.

Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 10XSSC (0.9 M saline/0.09 M sodium citrate) and remain  
5 bound when subjected to washing at 55°C in 1XSSC. Sequence identity may be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0.1XSSC (9 mM saline/0.9 mM sodium citrate). By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes may be any species, e.g. primate species, particularly human; rodents, such as rats and mice, canines, felines, bovines,  
10 ovines, equines, yeast, nematodes, *etc.*

Between mammalian species, e.g. human and mouse, homologs have substantial sequence similarity, *i.e.* at least 75% sequence identity between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, *etc.* A reference sequence will  
15 usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul *et al.* (1990) J Mol Biol. 215:403-10. The sequences provided herein are utilized for recognizing *cos2* related and homologous proteins in database searches.

20

#### COS2 NUCLEIC ACID COMPOSITIONS

Nucleic acids encoding *cos2* may be cDNA or genomic DNA or a fragment thereof. The term "*cos2* gene" shall be intended to mean the open reading frame encoding specific *cos2* polypeptides, introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either  
25 direction. The gene may be introduced into an appropriate vector for extrachromosomal maintenance or for integration into the host.

The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous  
30 exons, with the intervening introns, when present, removed by nuclear RNA splicing, to create a continuous open reading frame encoding a *cos2* protein.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It may further include the 3' and 5' untranslated regions  
35 found in the mature mRNA. It may further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, *etc.*, including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal

sequence. The genomic DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue and stage specific expression.

5 The sequence of the 5' flanking region may be utilized for promoter elements, including enhancer binding sites, that provide for developmental regulation in tissues where *cos2* is expressed. The tissue specific expression is useful for determining the pattern of expression, and for providing promoters that mimic the native pattern of expression. Naturally occurring polymorphisms in the promoter region are useful for determining natural variations in expression, particularly those that may be associated with disease.

10 Alternatively, mutations may be introduced into the promoter region to determine the effect of altering expression in experimentally defined systems. Methods for the identification of specific DNA motifs involved in the binding of transcriptional factors are known in the art, e.g. sequence similarity to known binding motifs, gel retardation studies, etc. For examples, see Blackwell *et al.* (1995) Mol Med 1: 194-205; Mortlock *et al.* (1996) Genome Res. 6: 327-33; and Joulin and  
15 Richard-Foy (1995) Eur J Biochem 232: 620-626.

The regulatory sequences may be used to identify *cis* acting sequences required for transcriptional or translational regulation of *cos2* expression, especially in different tissues or stages of development, and to identify *cis* acting sequences and *trans* acting factors that regulate or  
20 mediate *cos2* expression. Such transcription or translational control regions may be operably linked to a *cos2* gene in order to promote expression of wild type or altered *cos2* or other proteins of interest in cultured cells, or in embryonic, fetal or adult tissues, and for gene therapy.

The nucleic acid compositions of the subject invention may encode all or a part of the subject polypeptides. Double or single stranded fragments may be obtained of the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction  
25 enzyme digestion, by PCR amplification, etc. For the most part, DNA fragments will be of at least 15 nt, usually at least 18 nt, more usually at least about 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening probes, etc. Larger DNA fragments, *i.e.* greater than 100 nt are useful for production of the encoded polypeptide. For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of the primer sequences is not  
30 critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art. It is preferable to choose a pair of primers that will generate an amplification product of at least about 50 nt, preferably at least about 100 nt. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. Amplification primers hybridize to complementary strands of DNA,  
35 and will prime towards each other.

The *cos2* genes are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a *cos2* sequence or fragment thereof, generally being at least about



50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The DNA may also be used to identify expression of the gene in a biological specimen. The manner in which one probes cells for the presence of particular nucleotide sequences, as genomic DNA or RNA, is well established in the literature and does not require elaboration here. DNA or mRNA is isolated from a cell sample. The mRNA may be amplified by RT-PCR, using reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the subject DNA sequences. Alternatively, the mRNA sample is separated by gel electrophoresis, transferred to a suitable support, *e.g.* nitrocellulose, nylon, *etc.*, and then probed with a fragment of the subject DNA as a probe. Other techniques, such as oligonucleotide ligation assays, *in situ* hybridizations, and hybridization to DNA probes arrayed on a solid chip may also find use. Detection of mRNA hybridizing to the subject sequence is indicative of *cos2* gene expression in the sample.

The sequence of a *cos2* gene, including flanking promoter regions and coding regions, may be mutated in various ways known in the art to generate targeted changes in promoter strength, sequence of the encoded protein, *etc.* The DNA sequence or protein product of such a mutation will usually be substantially similar to the sequences provided herein, *i.e.* will differ by at least one nucleotide or amino acid, respectively, and may differ by at least two but not more than about ten nucleotides or amino acids. The sequence changes may be substitutions, insertions or deletions. Deletions may further include larger changes, such as deletions of a domain or exon. Other modifications of interest include epitope tagging, *e.g.* with the FLAG system, HA, *etc.* For studies of subcellular localization, fusion proteins with green fluorescent proteins (GFP) may be used.

Techniques for *in vitro* mutagenesis of cloned genes are known. Examples of protocols for site specific mutagenesis may be found in Gustin *et al.*, *Biotechniques* 14:22 (1993); Barany, *Gene* 37:111-23 (1985); Colicelli *et al.*, *Mol Gen Genet* 199:537-9 (1985); and Prentki *et al.*, *Gene* 29:303-13 (1984). Methods for site specific mutagenesis can be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, CSH Press 1989, pp. 15.3-15.108; Weiner *et al.*, *Gene* 126:35-41 (1993); Sayers *et al.*, *Biotechniques* 13:592-6 (1992); Jones and Winistorfer, *Biotechniques* 12:528-30 (1992); Barton *et al.*, *Nucleic Acids Res* 18:7349-55 (1990); Marotti and Tomich, *Gene Anal Tech* 6:67-70 (1989); and Zhu, *Anal Biochem* 177:120-4 (1989). Such mutated genes may be used to study structure-function relationships of *cos2*, or to alter properties of the protein that affect its function or regulation.

#### COS2 POLYPEPTIDES

The subject gene may be employed for producing all or portions of *cos2* polypeptides. For expression, an expression cassette may be employed. The expression vector will provide a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation

region, and a transcriptional and translational termination region. These control regions may be native to a *cos2* gene, or may be derived from exogenous sources.

The peptide may be expressed in prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression. For large scale production of the protein, a unicellular organism, such as *E. coli*, *B. subtilis*, *S. cerevisiae*, insect cells in combination with baculovirus vectors, or cells of a higher organism such as vertebrates, particularly mammals, e.g. COS 7 cells, may be used as the expression host cells. In some situations, it is desirable to express the *cos2* gene in eukaryotic cells, where the *cos2* protein will benefit from native folding and post-translational modifications. Small peptides can also be synthesized in the laboratory. Peptides that are subsets of the complete *cos2* sequence, e.g. peptides of at least about 8 amino acids in length, usually at least about 12 amino acids in length, and may be as many as about 20 amino acids in length, up to substantially the length of the intact protein, may be used to identify and investigate parts of the protein important for function, such as the Ci or microtubule binding domains, the kinesin-like "motor", or to raise antibodies directed against these regions.

With the availability of the protein or fragments thereof in large amounts, by employing an expression host, the protein may be isolated and purified in accordance with conventional ways. A lysate may be prepared of the expression host and the lysate purified using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification technique. The purified protein will generally be at least about 80% pure, preferably at least about 90% pure, and may be up to and including 100% pure. Pure is intended to mean free of other proteins, as well as cellular debris.

The expressed *cos2* polypeptides are used for the production of antibodies, where short fragments provide for antibodies specific for the particular polypeptide, and larger fragments or the entire protein allow for the production of antibodies over the surface of the polypeptide. Antibodies may be raised to the wild-type or variant forms of *cos2*. Antibodies may be raised to isolated peptides corresponding to these domains, or to the native protein.

Antibodies are prepared in accordance with conventional ways, where the expressed polypeptide or protein is used as an immunogen, by itself or conjugated to known immunogenic carriers, e.g. KLH, pre-S HBsAg, other viral or eukaryotic proteins, or the like. Various adjuvants may be employed, with a series of injections, as appropriate. For monoclonal antibodies, after one or more booster injections, the spleen is isolated, the lymphocytes immortalized by cell fusion, and then screened for high affinity antibody binding. The immortalized cells, i.e. hybridomas, producing the desired antibodies may then be expanded. For further description, see Monoclonal Antibodies: A Laboratory Manual, Harlow and Lane eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, 1988. If desired, the mRNA encoding the heavy and light chains may be isolated and mutagenized by cloning in *E. coli*, and the heavy and light chains mixed to further enhance the affinity of the antibody. Alternatives to *in vivo* immunization as a method of raising antibodies include binding to phage "display" libraries, usually in conjunction with *in vitro* affinity maturation.

## DIAGNOSTIC USES

The subject nucleic acid and/or polypeptide compositions may be used to analyze a patient sample for the presence of polymorphisms associated with a disease state or genetic predisposition to a disease state. Biochemical studies may be performed to determine whether a sequence polymorphism in a *cos2* coding region or control regions is associated with disease, particularly developmental abnormalities, cancers, e.g. basal cell carcinoma, glioma, medulloblastoma, meningioma, breast carcinoma, etc. Disease associated polymorphisms may include mutations that alter expression level, that affect the binding activity of the protein to Ci or to microtubules, that alter the subcellular localization of *cos2*, etc.

Changes in the promoter or enhancer sequence that may affect expression levels of *cos2* can be compared to expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as b-galactosidase, luciferase, chloramphenicol acetyltransferase, etc. that provides for convenient quantitation; and the like.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, e.g. a disease associated polymorphism. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express *cos2* may be used as a source of mRNA, which may be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki, *et al.* (1985) Science **239**:487, and a review of techniques may be found in Sambrook, *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2–14.33. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, for examples see Riley *et al.* (1990) N.A.R. **18**:2887-2890; and Delahunty *et al.* (1996) Am. J. Hum. Genet. **58**:1239-1246.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g. <sup>32</sup>P, <sup>35</sup>S, <sup>3</sup>H; etc. The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc., where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, *e.g.* amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or other methods; and the sequence of bases compared to a wild-type *cos2* sequence. Hybridization with the variant sequence may also be used to determine its presence, by Southern blots, dot blots, *etc.* The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilised on a solid support, as described in US 5,445,934, or in WO95/35505, may also be used as a means of detecting the presence of variant sequences. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Screening for mutations in *cos2* may be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that may affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in *cos2* proteins may be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded *cos2* protein in regulation of *Ci* (*GLI*), transport and/or sequestration of transcription factors, *etc.*, may be determined by comparison with the wild-type protein.

Antibodies specific for a *cos2* may be used in staining or in immunoassays. Samples, as used herein, include biological fluids such as semen, blood, cerebrospinal fluid, tears, saliva, lymph, dialysis fluid and the like; organ or tissue culture derived fluids; and fluids extracted from physiological tissues. Also included in the term are derivatives and fractions of such fluids. The cells may be dissociated, in the case of solid tissues, or tissue sections may be analyzed. Alternatively a lysate of the cells may be prepared.

Diagnosis may be performed by a number of methods to determine the absence or presence or altered amounts of normal or abnormal *cos2* in patient cells. For example, detection may utilize staining of cells or histological sections, performed in accordance with conventional methods. Cells are permeabilized to stain cytoplasmic molecules. The antibodies of interest are added to the cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody may be labeled with radioisotopes, enzymes, fluorescers, chemilumescers, or other labels for direct detection. Alternatively, a second stage antibody or reagent is used to amplify the signal. Such reagents are well known in the art. For example, the primary antibody may be conjugated to biotin, with horseradish peroxidase-conjugated avidin added as a second stage reagent. Alternatively, the secondary antibody conjugated to a fluorescent compound, *e.g.* fluorescein, rhodamine, Texas red, *etc.* Final detection uses a substrate

that undergoes a color change in the presence of the peroxidase. The absence or presence of antibody binding may be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc.

5

## MODULATION OF GENE EXPRESSION

The *cos2* genes, gene fragments, or the encoded protein or protein fragments are useful in gene therapy to treat disorders associated with *cos2* defects. Expression vectors may be used to introduce the *cos2* gene into a cell. Such vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences. Transcription cassettes may be prepared comprising a transcription initiation region, the target gene or fragment thereof, and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, e.g. plasmid; retrovirus, e.g. lentivirus; adenovirus; and the like, where the vectors are able to transiently or stably be maintained in the cells, usually for a period of at least about one day, more usually for a period of at least about several days to several weeks.

The gene or *cos2* protein may be introduced into tissues or host cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth *et al.* (1992) Anal Biochem 205:365-368. The DNA may be coated onto gold microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature (see, for example, Tang *et al.* (1992) Nature 356:152-154), where gold microprojectiles are coated with the *cos2* or DNA, then bombarded into skin cells.

Antisense molecules can be used to down-regulate expression of *cos2* in cells. The antisense reagent may be antisense oligonucleotides (ODN), particularly synthetic ODN having chemical modifications from native nucleic acids, or nucleic acid constructs that express such antisense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, e.g. by reducing the amount of mRNA available for translation, through activation of RNase H, or steric hindrance. One or a combination of antisense molecules may be administered, where a combination may comprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides will generally be at least about 7, usually at least about 12, more usually at least about 20 nucleotides in length, and not more than about 500, usually not more than about 50, more usually not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It has been found that short oligonucleotides, of from 7 to 8 bases in length, can be

strong and selective inhibitors of gene expression (see Wagner *et al.* (1996) Nature Biotechnology 14:840-844).

5 A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of a specific sequence for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene in an *in vitro* or animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense complementation.

10 Antisense oligonucleotides may be chemically synthesized by methods known in the art (see Wagner *et al.* (1993) *supra.* and Milligan *et al.*, *supra.*) Preferred oligonucleotides are chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

15 Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH<sub>2</sub>-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Sugar modifications are also used to enhance stability and  
20 affinity. The α-anomer of deoxyribose may be used, where the base is inverted with respect to the natural β-anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for  
25 deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, *e.g.* ribozymes, anti-sense conjugates, *etc.* may be used to inhibit gene expression. Ribozymes may be  
30 synthesized *in vitro* and administered to the patient, or may be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (for example, see International patent application WO 9523225, and Beigelman *et al.* (1995) Nucl. Acids Res. 23:4434-42). Examples of oligonucleotides with catalytic activity are described in WO 9506764. Conjugates of anti-sense ODN with a metal complex, *e.g.* terpyridylCu(II), capable of mediating mRNA hydrolysis are  
35 described in Bashkin *et al.* (1995) Appl Biochem Biotechnol 54:43-56.

GENETICALLY ALTERED CELL OR ANIMAL MODELS FOR *COSTAL2* FUNCTION

The subject nucleic acids can be used to generate transgenic animals or site specific gene modifications in cell lines. Transgenic animals may be made through homologous recombination, where the normal *costal2* locus is altered. Alternatively, a nucleic acid construct is randomly  
5 integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like.

The modified cells or animals are useful in the study of *costal2* function and regulation. For example, a series of small deletions and/or substitutions may be made in the *costal2* gene to determine the role of different exons in oncogenesis, signal transduction, etc. Of interest are the  
10 use of *cos2* to construct transgenic animal models for cancer, where expression of *cos2* is specifically reduced or absent, e.g. in skin cells, brain cells, etc. For models of skin abnormalities, one may use a skin-specific promoter to drive expression of the transgene, or other inducible promoter that can be regulated in the animal model. Such promoters include keratin gene promoters. Specific constructs of interest include anti-sense *cos2*, which will block *cos2* expression,  
15 expression of dominant negative *cos2* mutations, and over-expression of HH genes. A detectable marker, such as *lac Z* may be introduced into the *costal2* locus, where upregulation of *costal2* expression will result in an easily detected change in phenotype.

One may also provide for expression of the *costal2* gene or variants thereof in cells or tissues where it is not normally expressed or at abnormal times of development. Thus, mouse  
20 models of spina bifida or abnormal motor neuron differentiation in the developing spinal cord are made available. In addition, by providing expression of *cos2* protein in cells in which it is not normally produced, one can induce changes in cell behavior, e.g. through *cos2* mediated transcription modulation. Production of specific neuron types, such as dopaminergic or serotonergic neurons, may be accomplished by altering *cos2* function.

25 *Hh* genes, which oppose *cos2* function, have been implicated in spermatogenesis and oogenesis. Manipulation of *cos2* may therefore lead to new treatments for infertility or new types of contraception. Inactivation of one allele of *patched* in mice allows them to grow to abnormally large size; overproduction of *patched* causes mice to be small. The functional relationship between *cos2* and *patched* means that *cos2* can be manipulated to control growth.

30 DNA constructs for homologous recombination will comprise at least a portion of the *costal2* gene with the desired genetic modification, and will include regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known  
35 in the art. For various techniques for transfecting mammalian cells, see Keyed *et al.* (1990) Methods in Enzymology 185:527-537.

For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e.g. mouse, rat, guinea pig, etc. Such cells are grown on an

appropriate fibroblast-feeder layer or grown in the presence of leukemia inhibiting factor (LIF). When ES or embryonic cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient  
5 time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of  
10 pseudopregnant females. Females are then allowed to go to term and the resulting offspring screened for the construct. By providing for a different phenotype of the blastocyst and the genetically modified cells, chimeric progeny can be readily detected.

The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations  
15 cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in *in vitro* culture. The transgenic animals may be any non-human mammal, such as laboratory animals, domestic animals, etc. The transgenic animals may be used in functional studies, drug screening, etc., e.g. to determine the effect of a candidate drug on GLI transcriptional activation, developmental abnormalities, etc.

20 Mice and humans heterozygous for patched mutations have numerous developmental defects and a high incidence of a variety of cancers. *cos2* heterozygotes are useful animal models for human disease. By intervening in intracellular rather than membrane signaling events, different drugs may be discovered using *cos2* vs. *patched* models.

#### 25 *IN VITRO* MODELS FOR COSTAL2 FUNCTION

The availability of a number of components in the *hedgehog* signaling pathway, including SHH, PTCH, Ci (GLI), FU, PKA and COS2, allows *in vitro* reconstruction of the pathway. Two or more of the components may be combined *in vitro*, and the behavior assessed in terms of activation of transcription of specific target sequences; modification of protein components, e.g. proteolytic  
30 processing, phosphorylation, methylation, etc.; ability of different protein components to bind to each other; utilization of ATP, GTP, etc. The binding and translocation along microtubules is of interest for *cos2* function. The components may be modified by sequence deletion, substitution, etc. to determine the functional role of specific domains.

Drug screening may be performed using an *in vitro* model, a genetically altered cell or  
35 animal, or purified *costal2* protein. One can identify ligands or substrates that bind to, modulate or mimic the action of *costal2*. Areas of investigation include the development of cancer treatments, wound healing, adverse effects of aging, metastasis, etc. The functional similarity of *costal2* and



*patched* gene products suggests that agents that modulate each of these protein activities will have similar activity, but different structures.

Drug screening identifies agents that provide a replacement for Cos2 function in abnormal cells. Agents that mimic its function, in terms of transcriptional down-regulation, *etc.*, are predicted to inhibit the process of oncogenesis. Conversely, agents that reverse Cos2 function may stimulate controlled growth and healing. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, and the like. The purified protein may also be used for determination of three-dimensional crystal structure, which can be used for modeling intermolecular interactions, such as microtubule or Ci binding, potential kinesin motor activity, *etc.*

The term "agent" as used herein describes any molecule, *e.g.* protein or pharmaceutical, with the capability of altering or mimicking the physiological function of *costa/2*. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, *i.e.* at zero concentration or below the level of detection.

Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, *etc.* to produce structural analogs.

Where the screening assay is a binding assay, one or more of the molecules may be joined to a label, where the label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemilumescers, enzymes, specific binding molecules, particles, *e.g.* magnetic particles, and the like. Specific binding molecules include pairs, such as

biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay. These include reagents  
5 like salts, neutral proteins, e.g. albumin, detergents, etc that are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc. may be used. The mixture of components are added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4 and 40 °C.  
10 Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hours will be sufficient.

Other assays of interest detect agents that mimic *costa/2* function, such as repression of target gene transcription, binding properties, etc. For example, an expression construct comprising a *costa/2* gene may be introduced into a cell line under conditions that allow expression. The level  
15 of *costa/2* activity is determined by a functional assay, as previously described. In one screening assay, candidate agents are added in combination with Ci protein, and the ability to prevent Ci activation is detected. In another assay, the ability of candidate agents to enhance Cos2 function is determined. Alternatively, candidate agents are added to a cell that lacks functional Cos2, and screened for the ability to reproduce Cos2 in a functional assay.

20 The interaction between *cos2* and microtubules is of interest for drug screening. Such assays may determine the effect of agents on *cos2* function, or investigate the specific binding parameters of *cos2* for microtubules. The main component of microtubules is tubulin protein. Soluble tubulin exists in the form of dimers of  $\alpha$  and  $\beta$  tubulin. The dimers consist of a pair of  $\alpha$  and  $\beta$  tubulin proteins, which are tightly bound. These soluble dimers reversibly assemble in large  
25 numbers and form microtubules. Normal cellular function requires that tubulin may exist both in the soluble and polymerized forms, depending on the needs of the cells. Each of the  $\alpha$  and  $\beta$  tubulin proteins exist under different forms, designated as isotypes. Isotypes differ among themselves by slight variations in their amino acid sequences, although they are identical for more than 90% of their sequence. These isotypes are present in various tissues at very different levels, some of the  
30 isotypes being expressed predominantly or exclusively in certain tissues.

A number of agents are known that affect microtubules. Colchicine binds stoichiometrically to soluble tubulin dimers, slowing or preventing their incorporation into microtubules. Vinca alkaloids (vinblastine, vincristine and vinorelbine) act similarly to colchicine but at a different tubulin binding site. Taxanes (paclitaxel and docetaxel) have the opposite effect, and enhance the  
35 polymerization of tubulin. These drugs are predicted to affect *cos2* function.

The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host for treatment of cancer, developmental abnormalities attributable to a defect in *costa/2* function, etc. The compounds may also be used to enhance

costa/2 function in wound healing, aging, etc. The inhibitory agents may be administered in a variety of ways, orally, topically, parenterally e.g. subcutaneously, intraperitoneally, by viral infection, intravascularly, etc. Topical treatments are of particular interest. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%. 5

The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically-active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents. 10

#### EXPERIMENTAL

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g. amounts, temperature, concentrations, etc.) but some experimental errors and deviations should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric. 15 20

*Molecular cloning and hybridizations.* Molecular biology techniques were carried out according to Sambrook *et al.* (1989). The *cos2* chromosome walk was initiated with a genomic clone ( $\lambda$ B47) and using a cosmid library made from an isogenic fly stock (iso-1). The progress of the walk and positions of deficiencies were determined by *in situ* hybridization of biotin-labeled DNA fragments to polytene chromosomes. Overlapping iso-1 genomic  $\lambda$  phage clones lying between Df(2R)*sple*<sup>D1</sup> and Df(2R)NCX11 were isolated, and positions of *cos2* mutations were determined using blots of *cos2* mutant genomic DNA. From 38 *cos2* cDNA clones recovered from a  $\lambda$ gt10, 0-3 hour embryonic, cDNA library and a plasmid-based imaginal disc cDNA library two approximately 25 full-length clones, D12 and D13, were found and sequenced. *In situ* hybridization of riboprobes to embryos and imaginal discs was carried out as described (Mathies *et al.* (1994) Development 120, 2799-2809). 30

*Germ line transformations.* The 6.1 kb *KpnI* (K6.1) and 9.5 kb *HindIII* (H9.5) genomic fragments were subcloned into pCaSpeR4. Transgenic flies were made according to Spradling and Rubin (1982) Science 218, 341-7, using *w*<sup>1118</sup> embryos as recipients. Seven independent K6.1 inserts and eight independent H9.5 inserts were recovered. 35

*Antibody preparation and immunoblotting.* Affinity-purified rat polyclonal antisera were prepared to two parts of Cos2. A 1.5 kb *SacI-EcoRI* (SR1.5) fragment, including the putative motor domain, and a 0.8 kb *EcoRI* (R0.8) fragment, including the N-terminal 19 heptad-repeats, were each subcloned into two different plasmid expression vectors, pATH10, Rimm and Pollard (1989) Gene 5 75, 323-327 and pGEX-2T (128/129). The pATH10 clones create *E. coli* TrpE-Cos2 fusion proteins which were used as immunogens. Each TrpE-Cos2 fusion protein was purified from the BL21 pLysS cell lysates as inclusion bodies, cut from SDS gels, and injected into rats. The pGEX-2T (128/129) clones create Glutathione-S-Transferase (GST)-Cos2 fusion proteins, which were used to affinity purify the rat antisera. Soluble GST-Cos2 fusion proteins were purified from BL21 pLysS 10 cells using glutathione-agarose beads and coupled to AminoLink <sup>®</sup> Plus chromatography columns (Pierce). Antibodies were eluted from columns with 4.5 M MgCl<sub>2</sub> and dialyzed against 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA and 0.01% NaN<sub>3</sub>.

Immunoblots were carried out as described (Harlow and Lane, 1988 Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory). After 7.5% SDS-PAGE, proteins were 15 transferred to Protran membrane (Schleicher and Schuell), and membranes were blocked with 5% nonfat dry milk for 2-6 hrs. Antibodies used are as follows: Cos2, rat polyclonal antisera (1:50); Ci, rat monoclonal (1:5);  $\alpha$ -Tubulin, mouse monoclonal (1:100); En, mouse monoclonal (1:500); DmKhc, DK410-7.1 mouse monoclonal (1:250); Sgg/Zw3, rabbit polyclonal (1:500); and all Horseradish Peroxidase (HRP) conjugated secondary antibodies (1:20,000, Jackson 20 ImmunoResearch Labs). HRP was detected with Chemiluminescence reagent (NEN).

Anterior or posterior fragments of wing discs were dissected from third instar larvae and transferred to 40 mM Tris pH 7.2, 250 mM NaCl, 5 mM EDTA, and 0.05% NP-40 on ice, 0.5 fragments/ $\mu$ l. Fragments stored at -80 °C were thawed and homogenized. Approximately 70 anterior and posterior disc fragment equivalents were analyzed by immunoblotting. 25

*Protein detection in embryos and discs.* Washed and dechorionated embryos were fixed with either heat and methanol, methanol, or formaldehyde. After fixation embryos were stored either at -20° C in methanol or taken through a rehydration series to prepare embryos for indirect immunofluorescence. Third instar larval imaginal discs were prepared for indirect 30 immunofluorescence as described by (Johnson *et al.* (1995) Development 121, 4161-4170). Samples were mounted in Vectashield™ H-1000 (Vector Laboratories Inc.) and examined by confocal microscopy. Antibodies used are as follows: Cos2, rat polyclonal antisera (1:5);  $\alpha$ -Tubulin, mouse monoclonal (1:25); Lamin, mouse monoclonal (1:40);  $\beta$ -gal, rabbit polyclonal (1:100, Cappel); and all fluorescent secondary antibodies (1:200, Jackson ImmunoResearch Labs).

*Microtubule-binding assays.* This assay was carried out according to Kellogg *et al.* (1989) J. Cell Biol. 109, 2977-2991, with some modifications. Briefly, 16 g of 2-10 hour Canton S embryos were homogenized in 32 mls of C buffer (50 mM HEPES, pH 7.6, 1 mM MgCl<sub>2</sub>, 1 mM EGTA and 35

protease inhibitors (0.5 mM DTT, 1.74 µg/ml PMSF, 1 mM benzamidine, 2 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, all from Sigma) on ice. A supernatant (S100) was prepared and five 5 ml aliquots were made. One aliquot received 40 µM taxol (Sigma) and 1 mM GTP (binding), three aliquots received 40 µM taxol, 1 mM GTP, 80 U/ml apyrase (Sigma), and 0.5 mM AMP-PNP (Boehringer-Mannheim) (binding, lanes 6 and 7, and extractions), one was not supplemented (- taxol). Aliquots were incubated at 25 °C for 20' and then on ice for 10'. 4.5 mls of each sample was layered over a 10% sucrose cushion and centrifuged at 48,000 x g for 30' at 4 °C. For the - taxol and both binding samples, supernatants were saved and pellets were washed and resuspended in 4.5 mls of CX buffer (C buffer supplemented with 10% glycerol, 25 mM KCl and protease inhibitors).

For the extraction samples, pellets were resuspended in 1 ml of CX buffer (supplemented with 40 µM taxol, 1 mM GTP and either 5 mM Mg-ATP or 5 mM Mg-ATP and 0.5 M KCl) and incubated on ice for 10 hours before centrifugation as before. The resulting supernatants were saved and pellets were resuspended in 1 ml of CX buffer. 15 µl of each sample (in 1X sample buffer) was separated by SDS-PAGE and immunoblotted.

15

*Chromatography.* A Sepharose 4B (Pharmacia) column (48.5 cm x 1.77 cm<sup>2</sup> equaling a bed volume (V<sub>b</sub>) of 86 ml, void volume (V<sub>o</sub>) = 28.5 ml) was calibrated with protein standards (Pharmacia) and operated at a pressure head of 64 cm with a flow rate of 17.5 ml/hr. Embryos were homogenized in TNE buffer (40 mM Tris pH 7.2, 250 mM NaCl, 0.5 mM EDTA, 10% glycerol, 0.05% NP-40 and 1 µg/ml nocodazole) + proteinase inhibitors (previously listed), a S100 protein extract was prepared as above and dialyzed against column running buffer overnight at 4 °C. The S100 was recentrifuged at 100,000 x g for 30' at 4 °C. The total protein concentration of the resulting S100 was determined (34 mg/ml) and 250 µl (8.5 mg) was loaded onto the column. Column runs were monitored by a UV-spectrophotometer at 0.D. A<sub>280</sub> and 1.5 ml fractions were collected. Proteins were precipitated with acetone and analyzed by immunoblot.

25

*Coimmunoprecipitation.* An embryonic extract (S43) prepared in TNE buffer + proteinase inhibitors was pre-incubated with Protein G Sepharose beads (Pharmacia) for 30' at 4 °C with rocking. Beads were pelleted in a microfuge (30") and the pellet saved for immunoblotting. 100 µl aliquots of the supernatant were transferred to fresh tubes and supplemented with 1 µl of rat polyclonal Cos2 antisera, 1 µl of rabbit polyclonal Ci antisera, or 1 µl of preimmune sera, and then rocked at 4°C for 30'. Protein G Sepharose beads were added and samples rocked for 2 h at 4 °C. Beads pelleted as before were washed 3 times with TNE buffer. Washed beads were centrifuged and pellets and supernatants were examined by immunoblotting.

35

*Somatic clones.* *cos2* mutant clones were made with *cos2*<sup>W1</sup>. Both P[w<sup>+</sup>; FRT]<sup>G13</sup> *cos2*<sup>W1</sup>/CyO flies and P[w<sup>+</sup>; FRT]<sup>G13</sup> P[hsp70-Myc] (G13-nM) flies were crossed separately with *yw* P[ry<sup>+</sup>; FLP]<sup>12</sup>, *CyO*/Sco flies. *yw* P[ry<sup>+</sup>; FLP]<sup>12</sup>; P[w<sup>+</sup>; FRT]<sup>G13</sup> *cos2*<sup>W1</sup>/CyO and *yw* P[ry<sup>+</sup>; FLP]<sup>12</sup>; G13-

nM/CyO siblings were crossed and after 2 days adults were transferred to fresh vials. Larvae were heat-shocked on days 2, 3, and 4 for one hour at 37 °C. Imaginal discs were dissected from third instar larvae 30' after a fourth one-hour heat shock. Discs were incubated with monoclonal antibodies 9E10 anti-Myc (Sigma, 1:500) and 2A1 anti-Ci (1:5) and prepared for indirect

5 immunofluorescence.

K6.1 was tested for the ability to rescue *cos2*<sup>2</sup>/*cos2*<sup>12</sup> embryonic lethality. *cos2*<sup>2</sup> behaves like a null allele and *cos2*<sup>12</sup> is a strong loss of function allele. (Upper cross) *cos2*<sup>2</sup> and *cos2*<sup>12</sup> fail to complement one another. *cos2*<sup>2</sup>/CyO represents both *cos2*<sup>2</sup>/CyO and *cos2*<sup>12</sup>/CyO genotypes.

(Lower cross) *cos2*<sup>2</sup>/CyO virgin females that possess an insertion of K6.1(2) were crossed to  
10 *cos2*<sup>12</sup>/CyO males lacking K6.1(2). All flies are *white*<sup>-</sup> (*w*). K6.1(2) carries mini-*w* and the orange eye color it confers was used to identify the K6.1(2) bearing chromosome.

## Results

*Molecular identification of cos2.* *cos2* is located on the right arm of the second chromosome  
15 within polytene interval 43B2; 43C1.2. A chromosome walk was initiated from a chromosome position proximal to *cos2* at 43B1 (Fig. 1A). *Df(2R)sple*<sup>D1</sup> (43A1.2;43B2) and *Df(2R)NCX11* (43C1.2; 44C1.2) complement *cos2* mutations and bracket the *cos2* locus. The chromosome walk spans the distance between their adjacent deficiency endpoints at positions \*70 and \*150 kb. *Df(2R)EW60* complements *cos2* mutations and removes DNA centered over position \*90 (Fig. 1A).  
20 *Df(2R)Drl*<sup>R+21</sup> fails to complement *cos2* mutations and lies distal of *Df(2R)EW60*. Together *Df(2R)EW60* and *Df(2R)NCX11* limit the DNA interval containing *cos2* to 60 kb (Fig. 1A, horizontal bracket).

In Figure 1(A), the thick horizontal bars (top) indicate the positions of four deficiencies relative to polytene chromosome positions and corresponding chromosome walk positions (middle).  
25 Thin horizontal bars (bottom) indicate the positions of overlapping cosmid clones. *cos2* lies within a 60 kb interval between *Df(2R)EW60* and *Df(2R)NCX11*. The thick line within this interval, overlapping 43B3 (+110), is enlarged in 1(B). 1(B) Four *cos2* mutations are close to two maternally expressed transcription units. Thick horizontal bars above the restriction map indicate positions of *cos2* mutations. Hatching indicates uncertain deficiency endpoints. *Df(2R)Drl*<sup>R+21</sup> and *Df(2R)cos2*<sup>2</sup>  
30 define a 5 kb interval (open bar) containing a portion of *cos2*. *cos2*<sup>V1</sup> is an insertion and *cos2*<sup>14</sup> is associated with RFLPs within a 1.9 kb *EcoRI* fragment. Thick arrows below the restriction endonuclease map indicate the positions and directions of transcription of *cos2* and *tull*. A 6.1 *KpnI* genomic fragment (K6.1, solid bar) fully rescues *cos2* embryonic lethality to adulthood. A 9.5 kb *HindIII* genomic fragment (H9.5, hatched bar) fails to rescue *cos2* embryonic lethality. B= *BamHI*,  
35 H= *HindIII*, K= *KpnI*, R= *EcoRI*, S= *Sall* and X= *XbaI*. (C) A blot containing total RNA from different embryonic stages and third instar larvae was hybridized to radioactive *cos2* and *rp49* probes. The *cos2* probe reveals a single 4.9 kb transcript. *rp49* serves as a loading control.

An analysis of the 60 kb region with genomic DNA blots reveals restriction fragment length polymorphisms (RFLPs) for several *cos2* mutations and places part or all of *cos2* within a 5 kb interval of DNA. *Df(2R)cos2<sup>2</sup>* behaves as an amorphic allele of *cos2* and has a 6.5 kb DNA deletion between positions \*108 and \*115. *Df(2R)Drl<sup>R+21</sup>* has a proximal endpoint which lies within the

5 *Df(2R)cos2<sup>2</sup>* deletion, between \*110 and \*111. Therefore, part or all of *cos2* must lie within the 5 kb region of their overlap, between \*110 and \*115. Two additional *cos2* alleles map to this region. *cos2<sup>VI</sup>* is a viable allele that displays adult pattern duplications in the presence of semi-dominant alleles of *Cos1*. *cos2<sup>VI</sup>* is associated with a 9 kb insertion at position \*112. In addition, *cos2<sup>14</sup>*, a strong hypomorphic allele, is associated with RFLPs between \*115 and \*117.

10 *cos2* is maternally active, so *cos2* mRNA is likely to be present in early embryos prior to the onset of zygotic transcription at 2.5 hours (h) after fertilization. Radioactive cDNA synthesized from 0-2 h, 4-8 h, or 8-16 h embryonic poly (A) <sup>+</sup> RNA was hybridized to blots containing the 60 kb *cos2* region. Two contiguous *Sall* fragments (1.2 kb and 6.3 kb) which overlap the 5 kb *cos2* region hybridize to the 0-2 h cDNA probe. cDNA clones overlapping the large *Sall* fragment were

15 recovered for two adjacent, divergently transcribed, maternally expressed transcription units.

To determine which transcription unit is *cos2*, genomic fragments containing either the proximal or distal transcription unit were tested for their ability to rescue *cos2* embryonic lethality. Transgenic flies were constructed carrying either a 6.1 kb genomic *KpnI* fragment (K6.1) containing the proximal transcription unit or a 9.5 kb genomic *HindIII* fragment (H9.5) containing the distal

20 transcription unit. A single copy of K6.1 is sufficient to rescue *cos2<sup>2</sup>/cos2<sup>12</sup>* embryos to adulthood (Table 1). The number of *cos2<sup>2</sup>/cos2<sup>12</sup>* adults suggests that K6.1 contains all or a substantial proportion of *cos2*. H9.5 does not rescue *cos2* embryonic lethality.

A 4.8 kb *cos2* cDNA hybridizes to a 4.9 kb transcript present at high levels during the first four hours of embryogenesis, moderate levels between four and twelve hours, and low levels for the

25 duration of embryogenesis. The transcript is also present during the third larval instar.

**Table 1**  
**Rescue of *cos2* Embryonic Lethality**  
♀ *cos2<sup>2</sup>/CyO; +/+* x *cos2<sup>12</sup>/CyO; +/+* ♂

# adults	
<i>cos2<sup>2</sup>/cos2<sup>12</sup></i>	0
<i>cos2<sup>2</sup>/CyO</i>	431

30

♀ <i>cos2<sup>2</sup>/CyO; K6.1/+</i> x <i>cos2<sup>12</sup>/CyO; +/+</i> ♂			
	# adults	expected ratios	observed ratios
<i>cos2<sup>2</sup>/cos2<sup>12</sup>; K6.1/+</i>	297	1	1.0
<i>cos2<sup>2</sup>/cos2<sup>12</sup>; +/+</i>	0	0	0
<i>cos2<sup>2</sup>/CyO; K6.1/+</i>	520	2	1.7
<i>cos2<sup>2</sup>/CyO; +/+</i>	530	2	1.8

35

K6.1 was tested for the ability to rescue *cos2*<sup>2</sup>/*cos2*<sup>12</sup> embryonic lethality. *cos2*<sup>2</sup> behaves like a null allele and *cos2*<sup>12</sup> is a strong loss of function allele. (Upper cross) *cos2*<sup>2</sup> and *cos2*<sup>12</sup> fail to complement one another. *cos2*<sup>2</sup>/CyO represents both *cos2*<sup>2</sup>/CyO and *cos2*<sup>12</sup>/CyO genotypes. (Lower cross) *cos2*<sup>2</sup>/CyO virgin females that possess an insertion of K6.1(2) were crossed to  
 5 *cos2*<sup>12</sup>/CyO males lacking K6.1(2). All flies are *white*<sup>-</sup> (*w*). K6.1(2) carries mini-*w* and the orange eye color it confers was used to identify the K6.1(2) bearing chromosome.

*cos2* encodes a kinesin heavy chain-related protein. The complete sequence of a 4.8 kb cDNA clone for *cos2* was determined, as was all of the genomic sequence flanking the cDNA in the  
 10 rescuing transgene. The cDNA sequence reveals a single large open reading frame (ORF). The putative translational start site matches the Drosophila consensus sequence well and contains codons common in other Drosophila genes. Multiple stop codons in all three reading frames are present upstream of the putative start codon. The surrounding genomic sequence contains three short ORFs which do not begin with methionine or match the usual pattern of Drosophila codon  
 15 usage.

*cos2* is predicted to encode a 1201 amino acid polypeptide with a molecular weight of 133kD. The N-terminal (residues 1-450) and C-terminal (residues 1050-1201) regions are predicted to form globular structures consisting of alternating  $\alpha$ -helices and  $\beta$ -sheets. The central region (residues 643-990) contains 36 heptad-repeats which are predicted to mediate the formation  
 20 of a stable homodimer through a parallel coiled-coil.

The sequence is shown in Figure 2A. The N-terminus contains three putative nucleotide-binding motifs, N1 (P-loop), shaded box; N2, thick underline; and N3, dotted underline (Vale, 1996) and two putative microtubule-binding motifs (open boxes). The central portion contains 36 heptad-repeats arranged in eight clusters (thin underlining). Figure 2(B) shows the predicted structure of Cos2.  
 25 Sequence analyses predict that the N- and C-termini adopt globular conformations and that the 36 heptad-repeats mediate the formation of a homodimer by forming a parallel coiled-coil.

Cos2 is similar to members of the kinesin protein family. Over a span of 254 N-terminal amino acids (residues 136-389) Cos2 is 25%-30% identical to the motor domains of different members of the kinesin gene family. Kinesins are molecular motor proteins that move along  
 30 microtubules powered by ATP-hydrolysis. Conventional Kinesin consists of two Kinesin heavy chains (Khc) and two Kinesin light chains (Klc). Khc consists of a N-terminal motor domain, a central domain made up of heptad-repeats, and a C-terminal putative "cargo" domain thought to bind vesicles to move them. The motor domain of Khc is sufficient to mediate ATP-dependent movement along microtubules *in vitro*.

Figure 2(C) shows an alignment of the putative *cos2* P-loop motif (N1) with those of representative members of the kinesin gene family, a consensus sequence for the family is shown at the bottom. Closed and shaded rectangles indicate identity and similarity, respectively. The four underlined residues are invariant within the kinesin gene family. The minus sign indicates an acidic  
 35



residue and X the absence of a consensus residue. The percent identity between *cos2* and the indicated kinesin family members is shown at the right.

Several motor domain motifs implicated in nucleotide (N)- or microtubule-binding are highly conserved within the kinesin family and are generally conserved in *Cos2*. For example, the nucleotide-binding motif 1 (N1 or P-loop) in *Cos2* is 50% identical to the kinesin gene family consensus sequence. Four residues strictly conserved in the family are present in *Cos2* but *Cos2* residues R177 and Q179 are significantly different. The N2 motif, SSRSH, in *Cos2* is replaced by SLPAH, while N3, DLAGS/TE, is conserved in *Cos2*. N4 is not present in *Cos2*. Although the residues required for microtubule-binding are not well defined, two motifs have been tentatively implicated: the strictly conserved DLL motif and the L12 motif. The L12 consensus sequence is  $\Phi$ I/VPY/FRN/D ( $\Phi$ =hydrophobic residues), both the P and R residues are strictly conserved (Goldstein, 1993 *Annu. Rev. Genet.* 27, 319-51). In *Cos2* the DLL motif is present while L12 is partially conserved, with the expected R being absent.

*Cos2* expression prior to germ band extension. Polyclonal rat antisera were raised against N- and C-terminal portions of *Cos2*. Both antisera were affinity purified and used to probe blots of embryo protein extracts. Both antisera reveal a single band of 175 kD. Preimmune antisera do not detect any protein on these blots. *Cos2* migrates much slower than its predicted size of 133 kD, perhaps due to post-translational modification. Both antisera also recognize endogenous and over-expressed *Cos2* in the cytoplasm of *Drosophila* S2 cultured cells.

Both affinity purified antisera were used to assess the expression of *Cos2* in early embryos and both give the same results. In syncytial stage embryos (stage 4), prior to cellularization, *Cos2* is distributed uniformly within the cortical cytoplasm, at apical and basal focal planes. Anti-lamin antibody (green) outlines the nuclei. *Cos2* is not detected within nuclei nor in association with microtubule spindles. In late syncytial blastoderm embryos just prior to cellularization *Cos2* accumulates between, and apical to, nuclei. A lateral view shows *Cos2* accumulation forming rays perpendicular to the surface of the embryo. Surface views along the apices of nuclei show *Cos2* accumulation forming a honeycomb pattern. *Cos2* is punctate rather than uniform within the honeycomb lattice.

*Cos2* is associated with furrow canals throughout cellularization. Furrow canals (fc) are located at the leading edge of newly forming membrane between adjacent somatic nuclei. During cellularization each furrow canal moves toward the basal end of the nuclei where they broaden, forming expanded furrow canals (efc), and then fuse with one another in a process that will seal off the new cells from the embryo's interior. *Cos2* is present at relatively high levels within each early furrow canal. At this time *Cos2* is also distributed uniformly at lower levels throughout the cortical cytoplasm and along new membrane trailing each furrow canal. *Cos2* is associated with expanded furrow canals prior to and after their fusion during late cellularization. In cellular blastoderm

embryos and after the onset of gastrulation Cos2 is in the cytoplasm and at the periphery of all cells. Cos2 transcripts are uniformly distributed in the early embryo.

*Cos2 levels are elevated in the anterior compartments of embryonic segments and imaginal discs.* In contrast to the uniform distribution of *cos2* mRNA in the germ band-extended embryo, Cos2 is present in a striped pattern. Faint stripes along the germ band are first observed in late stage 9 embryos and become prominent by stage 10. Each stripe is continuous along the dorsal-ventral axis in both the ectoderm and the underlying mesoderm. The stripes persist throughout stage 11 and decay during germ band retraction (stage 12). The stripes appear to form just anterior of parasegmental grooves in anterior compartment cells, but precise determination of boundaries is difficult due to weak signal.

The accumulation of Cos2 in imaginal discs is reminiscent of its expression in the germ band extended embryo. *In situ* hybridizations with single-stranded sense and antisense *cos2* probes show that *cos2* mRNA is uniform within wing discs. In contrast Cos2 levels are elevated in the anterior compartment. A *ptc-lacZ* enhancer trap stock (AT90), producing nuclear localized  $\beta$ -galactosidase ( $\beta$ -gal) in a *ptc*-specific pattern, was used to show that the position of the A/P border corresponds to the line of transition from high to low Cos2 levels.

The apparent elevation of Cos2 in the anterior could be due to higher protein levels, to differential fixation of Cos2, or to the accessibility of Cos2 to antibodies. We confirmed that the amount of protein is regulated by dissecting anterior and posterior portions of wing discs and measuring protein levels on blots. The amount of Cos2 (C2), Ci and Engrailed (E) protein was normalized to the amount of  $\alpha$ -Tubulin (T) in the two fractions. Although Cos2 is present in the posterior disc extract, it is less abundant than in the anterior disc extract in keeping with the histochemical staining result. The Cos2 detected in the posterior disc extract has a slower mobility than the anterior protein, suggesting it is a distinct post-translational form of Cos2. As expected, Ci and En were detected only in anterior and posterior disc extracts, respectively.

*Cos2 and Ci associate with microtubules in embryo extracts.* A hallmark of kinesins is the ability to bind taxol-stabilized microtubules. It was tested whether Cos2 from fly embryos also binds microtubules. Embryo extracts were supplemented with taxol and centrifuged to bring down microtubules and associated proteins. In the absence of taxol, Cos2, Kinesin heavy chain (Khc), and  $\alpha$ -Tubulin are in the supernatant. In the presence of taxol,  $\alpha$ -Tubulin is in the pellet, showing that microtubules have formed efficiently. While Cos2 pellets, Khc remains in the supernatant because kinesin does not bind microtubules in the presence of the ATP contributed by the embryo extract. In the presence of the non-hydrolyzable ATP-analogue AMP-PNP, and apyrase which breaks down ATP, both Khc and Cos2 are in the microtubule pellet. Therefore, Cos2 binds microtubules in a taxol-dependent, ATP-insensitive manner, while Khc binds microtubules in a taxol-

dependent, ATP-sensitive manner. A bacterially expressed Cos2-GST fusion protein, containing the putative motor domain, also binds to purified microtubules.

We also tested whether Ci associates with microtubules, since so much Ci is cytoplasmic. Ci associates with microtubules just as Cos2 does, in a taxol-dependent, ATP-insensitive manner.

- 5 A slight amount of Ci sedimenting in the absence of taxol was not consistently observed.

The microtubule-association of Cos2 and Ci is stable in the presence of ATP. Microtubule pellets containing Cos2, Ci and Khc were washed and resuspended in the presence of taxol and 5 mM ATP and recentrifuged. Khc is partially extracted into the supernatant with just ATP, as expected. However, both Cos2 and Ci remain microtubule-associated in the presence of ATP.

- 10 Cos2, Ci, and Khc are completely extracted from microtubules in the presence of 5mM ATP and 0.5M KCl. Most microtubules dissolve in the high salt, but some remain intact. Shaggy/Zeste-white3 (Sgg/Zw3) protein, a kinase not expected to bind microtubules, serves as a control. A slight amount of Sgg/Zw3 cosediments with microtubules.

Although a substantial fraction of the soluble Cos2 is microtubule-associated, some is not.

- 15 Embryos stained with antibodies to  $\alpha$ -Tubulin and Cos2 reveal an overlap between Cos2 and microtubules but not a strict colocalization. Presumably not all of the Cos2 is microtubule-associated *in vivo*, consistent with the *in vitro* microtubule-binding results.

- Cos2 and Ci physically associate.* The similar microtubule-association of Cos2 and Ci suggested the two proteins might be in a protein complex. It was tested whether Cos2 and Ci coelute from a gel filtration column. A S100 embryo extract was separated on a Sepharose 4B column and fractions were assayed for Cos2, Ci, and  $\alpha$ -Tubulin by immunoblotting. The elution profiles for Cos2 and Ci are virtually identical. Their common peak fraction is approximately 500-600 kD. A homodimer of Cos2 is expected to elute with an approximate peak of 350 kD.  $\alpha$ -Tubulin elutes with an apparent molecular weight of 110 kD, consistent with the expected size of  $\alpha/\beta$ -Tubulin heterodimers. Because microtubules are efficiently depolymerized under the conditions used, the coelution of Cos2 and Ci is not dependent on microtubule-mediated crosslinking of the two proteins.

- It was tested whether Cos2 and Ci are associated in a protein complex using immunoprecipitation. Anti-Cos2 and anti-Ci antibodies nearly completely precipitate Cos2 and Ci, respectively. A significant fraction of Ci is coprecipitated by anti-Cos2 antibodies and vice versa. Cos2 preimmune antisera alone do not precipitate Cos2 or Ci, nor do Protein G Sepharose beads alone.

- 35 *cos2 somatic clones have increased cytoplasmic Ci staining and cause pattern duplications.* The FLP recombinase-FRT technique was employed to generate homozygous clones of *cos2* in wing discs and examine the location of Ci. Approximately 50% of flies genetically competent to form *cos2* somatic clones display extra wing veins and/or dramatic mirror-image duplications

characteristic of *cos2* mutants. *cos2* clones, marked by the loss of the Myc epitope carried on the other chromosome are frequently observed in both the A and P compartments of wing discs. Elevated cytoplasmic Ci staining is seen in *cos2* clones in the A compartment. The level of Ci staining is independent of the clone's distance from the A/P border or size. Nuclear Ci is not evident in the clones. *cos2* clones in the P compartment do not express *ci*.

*Cos2 is a divergent member of the diverse kinesin gene family.* The Cos2 sequence resembles kinesin, but Cos2 does not appear to belong to an existing kinesin subfamily and may have novel properties. Phylogenetic subfamilies have been established based on structural and functional similarities between motor domains. Some subfamilies are implicated in microtubule-based vesicle or organelle movement, while others participate in assembly or force generation for mitotic or meiotic microtubule spindles. The motor domain motifs implicated in nucleotide-binding in other kinesins are different in Cos2, so Cos2 may lack motor activity. Most kinesin motor proteins release microtubules when provided with ATP, an intrinsic property of the motor domain. In contrast, Cos2 remains attached to microtubules when exogenous ATP is provided. This suggests that unlike kinesin and many kinesin-related proteins, Cos2 may not regulate its binding to microtubules by ATP hydrolysis. The nucleotide-binding motifs of Cos2 may be unable to coordinate ATP.

The unconventional nature of Cos2 is also manifested in its localization in early embryos. Prior to somatic cell formation Cos2 accumulates in a honeycomb pattern at the cortex of the embryo. A similar lattice pattern is characteristic of actin and actin-associated proteins. Slightly later, during cellularization, Cos2 is associated with the actin-rich furrow canals, and the periphery of cells after cellularization. SMY1, a divergent kinesin-related protein, also localizes to actin-rich regions of the cell and has been implicated in two actin-based processes: polarized growth and secretion in yeast.

*Cos2 levels are post-transcriptionally elevated in the anterior compartment.* Because *cos2* mRNA levels are uniform, the elevated level of Cos2 in the A cells must be due to differences between A and P cells in either the production or the stability of Cos2. The uniform level of Cos2 throughout the anterior compartment of imaginal discs is inconsistent with Hh signal regulating its accumulation. Hh regulates Ci post-transcriptionally in the anterior compartment, but the limited range of Hh results in a graded distribution of Ci across the anterior compartment quite unlike the Cos2 distribution. A uniform anterior- or posterior-specific activity could establish the high uniform level of Cos2 in the anterior compartment. One possibility is that the moderate level of Ci in all A cells is sufficient to stabilize Cos2 in a complex. In P cells Cos2 would turn over more rapidly because it is not protected by complex formation. Another possibility is that Ci heightens translation of *cos2* mRNA, a possible role for the Ci zinc-finger protein in the cytoplasm. Alternatively a factor controlled by *en* could destroy Cos2 in P cells or stabilize it in A cells. *cos2* is not required for

patterning the posterior compartment, so the low level of Cos2 detected in the posterior disc extract may be non-functional.

*Cos2 may directly inhibit Ci from activating Hh target genes.* Previous genetic evidence indicates that *cos2* functions in A cells to regulate Hh target gene expression. The findings described above are consistent with these genetic data. First, Cos2 accumulates to high levels in A cells. Second, Cos2 physically associates with Ci, which is expressed in A cells. Third, *cos2* activity reduces Ci staining in A cells. *cos2* somatic clones in the anterior compartment of wing discs express high levels of Ci and cause mirror-image duplications of the wing. These pattern duplications are predicted to result from Ci-mediated activation of *dpp* within *cos2* clones. Cos2 and Ci may act in a large protein complex in the cytoplasm of A cells to mediate the regulation of Hh target genes.

The control of Hh target gene expression may depend on the level and/or post-translational form of Ci. When increased Ci is produced in wing discs far from the A/P border, beyond the influence of Hh, *dpp* and *ptc* transcription are activated in A cells. Because *dpp* and *ptc* are also activated in P cells, the Ci-mediated activation of these targets does not depend on an A compartment-specific factor. Ci may normally require a Hh-dependent modification to activate Hh targets, but elevated Ci seems sufficient to activate Hh targets. Along the A/P border Ci levels are post-transcriptionally elevated in response to Hh signalling. This elevated level of Ci is thought to allow it to enter the nucleus and directly activate Hh targets. Although nuclear Ci is hard to see, when the C-terminal portion of an epitope-tagged Ci is removed, leaving the zinc-fingers intact, Ci protein appears in the nucleus and the cytoplasm. Ci therefore appears competent to enter the nucleus but is normally restricted to the cytoplasm by the C-terminal tail. The absence of detectable Ci in the nucleus may be the result of inadequate Ci antibodies.

The protein complex we have identified could control the level of Ci and its subcellular distribution. The Cos2/Ci complex may control the level of Ci either by increasing Ci production or decreasing its degradation. The complex could protect Ci from proteases only when Hh signal is received, or the complex could associate with polysomes to facilitate translation of *ci* mRNA. Because a substantial fraction of Cos2 and Ci are associated, Cos2 may sequester Ci in the cytoplasm, possibly by tethering it to the cytoskeleton. Because Ci lacks an obvious nuclear localization signal its movement to the nucleus may be regulated by its ability to couple to a protein that carries it there. The transcription factor dCBP may serve this function. Cos2 may render Ci unavailable to such a protein except along the A/P border where Cos2 is inhibited. The absence of detectable nuclear Ci after eliminating *cos2* function may result from redundancy in the retention of Ci in the cytoplasm and/or inadequate Ci antibodies.

The identification of the Cos2/Ci complex helps to fill in missing steps in Hh signaling by showing direct interactions among two of the five known signal transduction components and by providing a cytoskeletal link. The importance of the complex is further underscored by the presence

of a third component, *fused*. The subcellular distribution of the complex may be important for controlling Hh targets and consequently cell differentiation.

5 In accordance with the subject invention, *costa/2* genes are provided, which can serve many purposes. The *costa/2* protein may be used in a screening for agonists and antagonists, and for assaying for the transcription of *cos2* mRNA. The protein or fragments thereof may be used to produce antibodies specific for the protein or specific epitopes of the protein. In addition, the gene may be employed for investigating embryonic development, by screening fetal tissue, preparing transgenic animals to serve as models, and the like.

10

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

15 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: Scott, Matthew  
Sisson, John
- (ii) TITLE OF THE INVENTION: Costal2 Genes and Their U  
ses
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Bozicevic & Reed LLP
  - (B) STREET: 285 Hamilton Avenue, Suite 200
  - (C) CITY: Palo Alto
  - (D) STATE: CA
  - (E) COUNTRY: USA
  - (F) ZIP: 94301
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette
  - (B) COMPUTER: IBM Compatible
  - (C) OPERATING SYSTEM: DOS
  - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 60/051,347
  - (B) FILING DATE: June 30, 1997
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Sherwood, Pamela J
  - (B) REGISTRATION NUMBER: 36,677
  - (C) REFERENCE/DOCKET NUMBER: SUN-65PCT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 650 327-3400
  - (B) TELEFAX: 650 327 3231
  - (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3605 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGGAAATAC	CCATTGAGGT	AGCGGTGCGC	ATCTTCCCGC	ATAGAGAGCT	CAAGGACTTG	60
TTGAGGAGCT	TCGGCCCCAC	AGAGCCCCAA	AAGGATGCGC	AGGCGGTGGA	TGAGGGGGCG	120
GACTCCAAGG	ACTCCGAGGC	TCAAGTTCCG	GCGGCTGAGA	AGGACAATCC	GTCAATTTC	180
GAGACGGACC	CAAACGGGAA	TGCTGAGCAG	GACAGTGCGG	CCGATTGCGA	GACAATTCCA	240
GATGCCAATG	GCAACGACAG	TGGTCAGAA	GATTACCCAG	ACTCCGCATA	TTGCGTTTCAG	300
GCTATTCCCA	TCAGCGCTTC	GGCCCTGGGA	TTGCCAGTG	CCCTGCCAGG	CGGAGATCCC	360
ATGGACAGCA	TTGCAGCTGG	ACTGATACAA	GTCGGTCCCC	ACACGGTTCC	GGTCACCCAC	420
GCCCTCCCCA	GCAGCAGCTC	CCAGGAGCAA	GTGTACCACC	AGACGGTCTT	TCCGCTCATC	480
ACCCTGTTCC	TGGAAGGTTT	CGACGCATCT	GTAGTCACCT	ATGGCCAGAG	GGGCCAGGGC	540
AAAAGCTACA	CACCTACGG	AAACGTCCAG	GACCTACTC	TGACGGATT	CACCGAAGGA	600
GTGCTCCAAT	TTGTGTCCG	TGACATTTTC	TACACATAT	CGTTGCACCC	AGAACGCACC	660
TATGCCATCA	ACGTGGGATT	CGTGGAAATT	TGCGGAGGTG	ATGTCTGCGA	CTTGTGGGGC	720
ATGGGAAACA	TACACTGCAC	CAACGTAGAT	GCCGTCTTCC	ACTGGTTGCA	GGTGGGTCTG	780
TCGGCCCCGC	AATCGTTGCC	GGCGCACACC	CTGTTACGCG	TTACCCTGGA	GCAGCAGTGG	840
GTGTCCAAGG	AGGGGCTGTT	GCAGCACC	TTGTCCACGG	CCAGTTTCTC	GGATCTCTGC	900
GGCACAGAGA	GATGTGGCGA	CCAGCCACCG	GGACGTCCTC	TCGATGCTGG	CCTGTGTATG	960
CTGGAGCAGG	TGATCAGTAC	TCTCACAGAT	CCAGGCCTCA	TGTACGGGGT	TAATGGCAAC	1020
ATCCCGTACG	GTCAGACCAC	GCTCACCCT	CTCCTGAAGG	ACTCGTTCGG	CGGACGGGCT	1080
CAGACGCTCG	TGATCCTGTG	CGTGTCACCG	CTGGAAGAGC	ACTTGCCCGA	AACTCTTGGC	1140
AACCTGCAGT	TCGCCTTTAA	GGTGCACTGC	GTACGTAATT	TTGTAATTAT	GAACACCTAC	1200
TCCGACGACA	ACACGATGAT	CGTTCAGCCG	GCTGAGCCTG	TTCCCCGAATC	CAATTCTCT	1260
GCTGGACCTT	TGTCGACGGC	GGGACCAGGG	GACAACTTTG	GCCTACAATT	CGCAGCGAGC	1320
CAATGGTCCA	AACCTAGTTAC	CAACGCCGAG	GGGCTATTTT	CCAAGCTGAT	AGACTCCAAG	1380
CTAATTACTG	AAGTGAGAA	GGAGCAGATC	GATGAGTGGC	TCTTCCTCAA	GCAGGAGTGC	1440
GAGGAGTGTC	TCAGCTCAAC	AGAGGCTATG	CGTCAGCAAA	AACAGTTGGT	TCCCATCTCTG	1500
GAGGCCGAGG	AGCCCGAGGA	CGTGAATTCT	GAAGCAGCCA	ATTCGGAGTC	GCCAACTCC	1560
GACAACGAAA	ACGACACAGA	CAATGAGTCG	CATCGGCCCG	ATCTGGACGA	CAAGATAGAA	1620
AGTCTAATGG	AAGAGTTTCG	CGACAAAACA	GACGCTCTTA	TACTTGAAAA	ACACGCTGAA	1680
TATCTATCCA	AGCATCCGAA	GGCGGTTATG	CAAAGCCAAG	ACCGCGAGAT	TGAGGCACAG	1740
CCGCCAGAAG	AAAATGGTGA	TGATCGAAAA	GTCAGCATTG	GCAGTCGCAG	GAGAAGTGTT	1800
CAGCCAGGTG	CTAGCTTAAG	TACTGCTGAG	CTTGCCATGC	TTAATCGGGT	AGCTTCCCAG	1860
CAGCCGCCTC	CGCCCATCGA	TCCTGAGTCG	CTGTCGATC	CTCTGGAAAG	TTCTTCGGGC	1920
GAAGGAATCC	GTCAGGCGGC	TCTCGCTGCC	GCCGCCGCCA	CTGCTCCTAT	TGAACAGCTG	1980
CAGAAAAAAT	TGCGCAAACT	GGTCGCTGAG	ATCGAGGGCA	AACAACGACA	GTTACGGGAA	2040
ATCGAAGAAC	AATCCAGGTA	AAACAAAATA	TAATCGCCGA	ATTGGTCAAG	AACAGCGATA	2100
CACGCAGCCA	TGCAAAGCAA	AGATTTCACA	AGAAACGTGC	CAAACTTGAG	GCCGAGTGCG	2160
ACAAGGCCAA	GAAGCAGTTA	GGTAAGGCGC	TAGTTCAAGG	CCGGGGTCAG	TCGGAGATTG	2220
AGCGATGGAC	CACGATAATC	GGACATCTCG	AGCGTCGACT	AGAAGACCTC	AGCTCAATGA	2280
AGCATATTGC	GGGTGAGAGC	GGACAGAAGG	TGAAGAAGCT	ACAGCAATCG	GTGGGCGAGT	2340
CGCGAAAAACA	GGCCGATGAT	TTACAGAAAA	AGCTTCGAAA	GGAGTGCAAG	CTGCGCTGCC	2400
AGATGGAGGC	GGAGCTGGTC	AAACTACGAG	AATCCAGGGA	GAAGTGCAAA	GAGCTAGTGA	2460
AGGCGCAAGG	TTCTCCCAG	CAACAAGGCC	GCCAGTTAA	GGCAGTACAG	GCTAGGATTA	2520
CGCACCTTAA	TCACATTTTA	CGCGAGAAGT	CGGATAACCT	GGAGRAGCAG	CCGGGACCAG	2580
AACAGCAGGA	GACCTTGCGT	CATGAGATCC	GCAACTTGCG	CGGAACCTCGT	GACTTGTTGT	2640
TGAAAGAACG	CTGTCAATTTG	GACCGCAAAC	TTAAGCGGGA	CAAGGTGCTG	ACGCAAAAGG	2700
AGGAGCGCAA	GCTGCTCGAG	TGCGATGAGG	CCATCGAGGC	CATAGATGCG	GCCATAGAAT	2760
TCAAGAACGA	GATGATCACG	GGCCACCGCT	CCATCGACAC	GAGCGACCGA	ATTACGCGGG	2820
AGAAGGGAGA	ACAGATGCTG	ATGGCACGCC	TAAATCGTCT	CTCAACGGAG	GAGATGCGAA	2880
CACTTCTGTA	CAAATACTTC	ACGAAGGTTA	TCGATTTGCG	CGACTCTTCA	CGAAAGCTGG	2940
AGTGCAGCT	GGTGCACTTG	GAGCGTGAGC	GGGATGCCTG	GGAGTGGAAG	GAGCGTGTTC	3000
TGTCCAATGC	CGTGCGCCAG	GCTAGACTGG	AAGGCGAACG	GAATGCGGGT	CTGCTGCAGC	3060
GCCAGCACGA	AATGAAACTC	ACTTTGATGC	TGCGTCACAT	GGCGGAGGAA	ACGTCGGCCA	3120
GTTCGGCCAG	CTACGGAGAA	CGAGCTTTGG	CCCCTGCCTG	TGTCGCCCCG	CCGGTGACAG	3180
CCAGTAGTGA	TTTCGACTAC	GATCATTTCT	ACAAAGGTGG	CGGCAATCCA	AGCAAGGCAC	3240



```

TGATCAAAGC GCCAAAGCCG ATGCCCACCG GCTCGGCGCT AGACAAATAC AAGGACAAAG 3300
AGCAACGCAG CGGACGCAAC ATCTTTGCCA AGTTCCATGT GCTCACCAGA TATGCGTCAG 3360
CTGCCGCAGC CGGTTTCCTCA GGGTCCACGG CCGAGGAATC CACGGCCCTG ATTGAGTCAA 3420
CCACCACGGC CACGGCAACC ACTACGTCGA CAACCACCAC TGGAGCCGTA GGAAAAGTGA 3480
AGGACAAGGC CCTGGTCAGC TTCAGGCCGG AGCAGCTGAA GCGTCTGATG CCAGCTCCGA 3540
CGGCCACGAA AGTGACGCGT CAGAAGAACA AGATAATTAT CCAGGACGCA AGTCGTCGAA 3600
ACTAA 3605

```

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1201 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Glu Ile Pro Ile Gln Val Ala Val Arg Ile Phe Pro His Arg Glu
 1             5             10             15
Leu Lys Asp Leu Leu Arg Ser Phe Gly Pro Thr Glu Pro Lys Lys Asp
      20             25             30
Ala Gln Ala Val Asp Glu Gly Ala Asp Ser Lys Asp Ser Glu Ala Gln
      35             40             45
Val Pro Ala Ala Glu Lys Asp Asn Pro Ser Ile Ser Glu Thr Asp Pro
      50             55             60
Asn Gly Asn Ala Glu Gln Asp Ser Ala Ala Asp Ser Lys Thr Ile Pro
      65             70             75             80
Asp Ala Asn Gly Asn Asp Ser Gly Gln Lys Asp Tyr Pro Asp Ser Ala
      85             90             95
Tyr Cys Val Gln Ala Ile Pro Ile Ser Ala Ser Ala Leu Gly Leu Pro
      100            105            110
Ser Ala Leu Pro Gly Gly Asp Pro Met Asp Ser Ile Ala Ala Gly Leu
      115            120            125
Ile Gln Val Gly Pro His Thr Val Pro Val Thr His Ala Leu Pro Ser
      130            135            140
Ser Ser Ser Gln Glu Gln Val Tyr His Gln Thr Val Phe Pro Leu Ile
      145            150            155            160
Thr Leu Phe Leu Glu Gly Phe Asp Ala Ser Val Val Thr Tyr Gly Gln
      165            170            175
Arg Gly Gln Gly Lys Ser Tyr Thr Leu Tyr Gly Asn Val Gln Asp Pro
      180            185            190
Thr Leu Thr Asp Ser Thr Glu Gly Val Val Gln Leu Cys Val Arg Asp
      195            200            205
Ile Phe Ser His Ile Ser Leu His Pro Glu Arg Thr Tyr Ala Ile Asn
      210            215            220
Val Gly Phe Val Glu Ile Cys Gly Gly Asp Val Cys Asp Leu Leu Gly
      225            230            235            240
Met Gly Asn Ile His Cys Thr Asn Val Asp Ala Val Phe His Trp Leu
      245            250            255
Gln Val Gly Leu Ser Ala Arg Gln Ser Leu Pro Ala His Thr Leu Phe
      260            265            270
Thr Leu Thr Leu Glu Gln Gln Trp Val Ser Lys Glu Gly Leu Leu Gln
      275            280            285

```

His Arg Leu Ser Thr Ala Ser Phe Ser Asp Leu Cys Gly Thr Glu Arg  
 290 295 300  
 Cys Gly Asp Gln Pro Pro Gly Arg Pro Leu Asp Ala Gly Leu Cys Met  
 305 310 315 320  
 Leu Glu Gln Val Ile Ser Thr Leu Thr Asp Pro Gly Leu Met Tyr Gly  
 325 330 335  
 Val Asn Gly Asn Ile Pro Tyr Gly Gln Thr Thr Leu Thr Thr Leu Leu  
 340 345 350  
 Lys Asp Ser Phe Gly Gly Arg Ala Gln Thr Leu Val Ile Leu Cys Val  
 355 360 365  
 Ser Pro Leu Glu Glu His Leu Pro Glu Thr Leu Gly Asn Leu Gln Phe  
 370 375 380  
 Ala Phe Lys Val Gln Cys Val Arg Asn Phe Val Ile Met Asn Thr Tyr  
 385 390 395 400  
 Ser Asp Asp Asn Thr Met Ile Val Gln Pro Ala Glu Pro Val Pro Glu  
 405 410 415  
 Ser Asn Ser Ser Ala Gly Pro Leu Ser Gln Ala Gly Pro Gly Asp Asn  
 420 425 430  
 Phe Gly Leu Gln Phe Ala Ala Ser Gln Trp Ser Lys Leu Val Thr Asn  
 435 440 445  
 Ala Glu Gly Leu Phe Ser Lys Leu Ile Asp Ser Lys Leu Ile Thr Glu  
 450 455 460  
 Val Glu Lys Glu Gln Ile Asp Glu Trp Leu Phe Leu Lys Gln Glu Cys  
 465 470 475 480  
 Glu Glu Cys Leu Ser Ser Thr Glu Ala Met Arg Gln Gln Lys Gln Leu  
 485 490 495  
 Val Pro Ile Leu Glu Ala Glu Glu Pro Glu Asp Val Asn Ser Glu Ala  
 500 505 510  
 Ala Asn Ser Glu Ser Pro Asn Ser Asp Asn Glu Asn Asp Thr Asp Asn  
 515 520 525  
 Glu Ser His Arg Pro Asp Leu Asp Asp Lys Ile Glu Ser Leu Met Glu  
 530 535 540  
 Glu Phe Arg Asp Lys Thr Asp Ala Leu Ile Leu Glu Lys His Ala Glu  
 545 550 555 560  
 Tyr Leu Ser Lys His Pro Lys Ala Val Met Gln Ser Gln Asp Arg Glu  
 565 570 575  
 Ile Glu Ala Gln Pro Pro Glu Glu Asn Gly Asp Asp Arg Lys Val Ser  
 580 585 590  
 Ile Gly Ser Arg Arg Arg Ser Val Gln Pro Gly Ala Ser Leu Ser Thr  
 595 600 605  
 Ala Glu Leu Ala Met Leu Asn Arg Val Ala Ser Gln Gln Pro Pro Pro  
 610 615 620  
 Pro Ile Asp Pro Glu Ser Val Val Asp Pro Leu Glu Ser Ser Ser Gly  
 625 630 635 640  
 Glu Gly Ile Arg Gln Ala Ala Leu Ala Ala Ala Ala Thr Ala Pro  
 645 650 655  
 Ile Glu Gln Leu Gln Lys Lys Leu Arg Lys Leu Val Ala Glu Ile Glu  
 660 665 670  
 Gly Lys Gln Arg Gln Leu Arg Glu Ile Glu Glu Thr Ile Gln Val Lys  
 675 680 685  
 Gln Asn Ile Ile Ala Glu Leu Val Lys Asn Ser Asp Thr Arg Ser His  
 690 695 700  
 Ala Lys Gln Arg Phe His Lys Lys Arg Ala Lys Leu Glu Ala Glu Cys  
 705 710 715 720  
 Asp Lys Ala Lys Lys Gln Leu Gly Lys Ala Leu Val Gln Gly Arg Gly  
 725 730 735

Gln Ser Glu Ile Glu Arg Trp Thr Thr Ile Ile Gly His Leu Glu Arg  
 740 745 750  
 Arg Leu Glu Asp Leu Ser Ser Met Lys His Ile Ala Gly Glu Ser Gly  
 755 760 765  
 Gln Lys Val Lys Lys Leu Gln Gln Ser Val Gly Glu Ser Arg Lys Gln  
 770 775 780  
 Ala Asp Asp Leu Gln Lys Lys Leu Arg Lys Glu Cys Lys Leu Arg Cys  
 785 790 795 800  
 Gln Met Glu Ala Glu Leu Val Lys Leu Arg Glu Ser Arg Glu Thr Gly  
 805 810 815  
 Lys Glu Leu Val Lys Ala Gln Gly Ser Pro Glu Gln Gln Gly Arg Gln  
 820 825 830  
 Leu Lys Ala Val Gln Ala Arg Ile Thr His Leu Asn His Ile Leu Arg  
 835 840 845  
 Glu Lys Ser Asp Asn Leu Glu Xaa Gln Pro Gly Pro Glu Gln Gln Glu  
 850 855 860  
 Thr Leu Arg His Glu Ile Arg Asn Leu Arg Gly Thr Arg Asp Leu Leu  
 865 870 875 880  
 Leu Lys Glu Arg Cys His Leu Asp Arg Lys Leu Lys Arg Asp Lys Val  
 885 890 895  
 Leu Thr Gln Lys Glu Glu Arg Lys Leu Leu Glu Cys Asp Glu Ala Ile  
 900 905 910  
 Glu Ala Ile Asp Ala Ala Ile Glu Phe Lys Asn Glu Met Ile Thr Gly  
 915 920 925  
 His Arg Ser Ile Asp Thr Ser Asp Arg Ile Gln Arg Glu Lys Gly Glu  
 930 935 940  
 Gln Met Leu Met Ala Arg Leu Asn Arg Leu Ser Thr Glu Glu Met Arg  
 945 950 955 960  
 Thr Leu Leu Tyr Lys Tyr Phe Thr Lys Val Ile Asp Leu Arg Asp Ser  
 965 970 975  
 Ser Arg Lys Leu Glu Leu Gln Leu Val Gln Leu Glu Arg Glu Arg Asp  
 980 985 990  
 Ala Trp Glu Trp Lys Glu Arg Val Leu Ser Asn Ala Val Arg Gln Ala  
 995 1000 1005  
 Arg Leu Glu Gly Glu Arg Asn Ala Val Leu Leu Gln Arg Gln His Glu  
 1010 1015 1020  
 Met Lys Leu Thr Leu Met Leu Arg His Met Ala Glu Glu Thr Ser Ala  
 025 1030 1035 1040  
 Ser Ser Ala Ser Tyr Gly Glu Arg Ala Leu Ala Pro Ala Cys Val Ala  
 1045 1050 1055  
 Pro Pro Val Gln Ala Ser Ser Asp Phe Asp Tyr Asp His Phe Tyr Lys  
 1060 1065 1070  
 Gly Gly Gly Asn Pro Ser Lys Ala Leu Ile Lys Ala Pro Lys Pro Met  
 1075 1080 1085  
 Pro Thr Gly Ser Ala Leu Asp Lys Tyr Lys Asp Lys Glu Gln Arg Ser  
 1090 1095 1100  
 Gly Arg Asn Ile Phe Ala Lys Phe His Val Leu Thr Arg Tyr Ala Ser  
 105 1110 1115 1120  
 Ala Ala Ala Ala Gly Ser Ser Gly Ser Thr Ala Glu Glu Ser Thr Ala  
 1125 1130 1135  
 Leu Ile Glu Ser Thr Thr Thr Ala Thr Ala Thr Thr Thr Ser Thr Thr  
 1140 1145 1150  
 Thr Thr Gly Ala Val Gly Lys Val Lys Asp Lys Ala Leu Val Ser Phe  
 1155 1160 1165

WO 99/00403

PCT/US98/12820

Arg Pro Glu Gln Leu Lys Arg Leu Met Pro Ala Pro Thr Ala Thr Lys

1170

1175

1180

Val Thr Arg Gln Lys Asn Lys Ile Ile Ile Gln Asp Ala Ser Arg Arg

185

1190



1195

1200

Asn


## WHAT IS CLAIMED IS:

1. A purified polypeptide composition comprising at least 50 weight % of the protein present as a Cos2 protein or a fragment thereof.
- 5 2. A purified polypeptide according to Claim 1, wherein said polypeptide comprises a loss of function mutation.
3. A purified polypeptide according to Claim 1, wherein said Cos2 protein comprises  
10 the amino acid sequence as set forth in SEQ ID NO:2.
4. A DNA molecule or fragment thereof of at least about 18 nucleotides as part of other than a naturally occurring chromosome, comprising a sequence encoding a protein according to any of claims 1 to 3, or a complement thereof.
- 15 5. A DNA molecule according to Claim 4, comprising a DNA sequence as set forth in SEQ ID NO:1.
6. An isolated DNA molecule according to any of claims 4 to 5, wherein said DNA  
20 molecule comprises a transcriptional initiation region 5' to said sequence encoding a Cos2 protein.
7. A cell comprising a DNA composition according to any of claims 4 to 6.
8. An array of oligonucleotides comprising one or more sequences according to any of  
25 claims 4 to 6.
9. An antibody specific for the polypeptide of any one of claims 1 to 3.
10. A method of screening for biologically active agents that modulate Cos2 function,  
30 the method comprising:  
combining a candidate biologically active agent with any one of:  
(a) a polypeptide according to any of claims 1 to 3; or  
(b) a cell according to claim 7; and  
determining the effect of said agent on Cos2 function.



2/2

1 MEIPIQVAVRIFPHRELKDLLRSFGPTEPKKDAQAVDEGADSKDSEAQVP  
 51 AA EKDNPSISETDPNGNAEQDSAADSKTIPDANGND SGQKDYPDSAYCVQ  
 101 AIPISASALGLPSALPGGDPMDSIAAGLIQVGPHTVPVTHALPSSSSSEQ  
 151 VYHQTVFPLITLFLEGF DASVVTY GQRGQGSYTL YGNVQDPTLTDSTEG  
 201 VVQLCVRDIFSHISLHPERTYAINVGFVEICGGDVC DLLGMGNIHCTNVD  
 251 AVFHWLQVGLSARQSL PAHTLFTLTLEQQWVSKEGLLQHRLSTASF SDLC  
 301 GTERCGDQPPGRPLDAGLCMLEQVISTLTDPGLMYGVNGNIPYGQTTLT  
 351 LLKDSFGGRAQTLVILCVSPLEEHLPETLGNLQFAFKVQCVRNFVIMNTY  
 401 SDDNTMIVQPAEPVPESNSSAGPLSQAGPGDNFGLQFAASQWSKLVTAE  
 451 GLFSKLIDSKLITEVEKEQIDEWLFLKQECCECLSTEAMRQQKQLVPI  
 501 EAEPEDVNSEAANSESPNSDNENDTDNESHPRDLDDKIESLMEEFRDKT  
 551 DALILEKHAEYLSKHPKAVMQSQDREIEAQPPEENGDDRKVSIGSRRRSV  
 601 QPGASLSTAELAMLNRVASQQPPPPIDPESVVDPLESSSGEG RQAALAA  
 651 AAATAP IEQLQKKLRKLVAE IEGKQRQLRE IEET IQVKQNI IAELVKNSD  
 701 TRSHAKQRFHKKRAKLEAECDAKKQLGKALVQGRGQSE IERWTTI IGHL  
 751 ERRLEDLSSMKHI AGESGQKVKKLQQSVGESRKQADDLQKKLRKECKLRC  
 801 QMEAE LVKLRESRETGKELVKAQGSPEQQGRQLKAVQAR ITHLNHI LREK  
 851 SDNLEXQPGPEQGETL RHEIRNLRGTRDLLLKERCHLDRKLKRDKVL TQK  
 901 EERKLLCEDEA IEAIDAAIEFKNEMI TGHRSIDTSDRI QREKGEQMLMAR  
 951 LNRLSTEEMRTL LYKYFTKVIDLRDSSRKLELQLVQLERERDAWEWKERV  
 1001 LSNAVRQARLEG ERNAVL LQRQHEMKLTLM LRHMAEETSASSASYGERAL  
 1051 APACVAPPVQASSDFDYDHFYKGGGNPSKAL IKAPKPMPTGSALDKYKDK  
 1101 EQRSGRNIFAKFHV LTRYASAAAAGSSGSTAEESTAL IESTTTATATTT  
 1151 TTTTGAVGKVKDKALVSFRPEQLKRLMPAPTATKVTRQKNK IIQDASRR  
 1201 N

**FIG. 2A****FIG. 2C**

C

	P-loop Alignment																		Motor Domain identity (%)						
Cos2	L	E	G	F	D	A	S	V	V	T	Y	G	Q	R	G	Q	G	K	S	Y	T	L	Y	G	100
BimC	L	A	G	Y	N	C	T	F	A	Y	G	Q	T	G	T	G	K	T	Y	T	M	S	G		28
HuKhc	L	E	G	Y	N	G	T	F	A	Y	G	Q	T	S	S	G	K	T	H	T	M	E	G		28
Kif3	L	E	G	Y	N	G	T	F	A	Y	G	Q	T	G	T	G	K	T	F	T	M	E	G		28
KipA	L	D	G	Y	N	V	C	F	C	Y	G	Q	T	G	S	G	K	T	H	T	M	S		30	
Smy1	L	N	G	Y	N	G	T	V	T	Y	G	P	S	F	S	G	K	S	Y	S	L	G		27	
Unc-104	F	E	G	Y	N	V	C	F	A	Y	G	Q	T	G	S	G	K	S	Y	T	M	M	G		28
DmKhc	L	A	G	Y	N	G	T	F	A	Y	G	Q	T	S	S	G	K	T	H	T	M	E	G		27
consensus	L	-	G	Y	N	X	T	I	F	A	Y	G	Q	T	G	S	G	K	T	Y	T	M	X	G	50

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/12820

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>																				
IPC(6) :C07H 21/02, 21/04; C07K 5/00+, 14/00+; C12N 1/21; C12Q 1/68 US CL :436/6, 320.1, 325; 530/300, 350; 536, 23.1, 24.3 According to International Patent Classification (IPC) or to both national classification and IPC																				
<b>B. FIELDS SEARCHED</b>																				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 436/6, 320.1, 325; 530/300, 350; 536, 23.1, 24.3																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS CAPLUS SCISEARCH BIOSIS MEDLINE EMBASE EMBL54 GENE BANK106																				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
A	GRAU, Y. et al. The Segment Polarity Gene costal-2 in Drosophila. Developmental Biology. 1987, Vol. 122, pages 186-200, see entire document.	1-5																		
P,Y	ROBBINS, D. J. et al. Hedgehog Elicits Signal Transduction by Means of a Large Complex Containing the Kinesin-Related Protein Costal2. Cell. 25 July 1997, Vol. 90, pages 225-234, see entire document.	1-5																		
P,X ---- P,Y	SISSON, J. C. et al. Costal2, a Novel Kinesin-Related Protein in the Hedgehog Signaling Pathway. Cell. 25 July 1997. Vol. 90, pages 235-245, see entire document.	1-5 ---- 9																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family																		
*O* document referring to an oral disclosure, use, exhibition or other means																				
*P* document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 28 JULY 1998		Date of mailing of the international search report <b>02 SEP 1998</b>																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Seán McGarry</i> SEAN MCGARRY Telephone No. (703) 308-0196																		



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/12820

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	SISSON, John Charles. A Novel Kinesin-Related Protein Involved in Drosophila Pattern Formation (Winless, Hedgehog). Dissertation Abstracts International. 1996, Vol. 57/08-B, page 4898, see entire abstract.	1-5 ---- 9

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/12820

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☒ Claims Nos.: 6-8, 10  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.